Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis

REFERENCES

1. 1.↵
   1. Consolaro A,
   2. Ravelli A

   . Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas—key to understanding etiology and genetic factors? J Rheumatol 2016;43:683–5.

   OpenUrlFREE Full Text
2. 2.↵
   1. Martini A

   . Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012;12:56–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Petty RE,
   2. Laxer RM,
   3. Lindsley CB,
   4. Wedderburn LR

   1. De Benedetti F,
   2. Schneider R

   . Systemic juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016:205–16.
4. 4.↵
   1. Minoia F,
   2. Davì S,
   3. Horne A,
   4. Demirkaya E,
   5. Bovis F,
   6. Li C,
   7. et al.

   Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66:3160–9.

   OpenUrl
5. 5.↵
   1. Ruperto N,
   2. Brunner HI,
   3. Quartier P,
   4. Constantin T,
   5. Wulffraat N,
   6. Horneff G,
   7. et al.

   Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396–406.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. De Benedetti F,
   2. Brunner HI,
   3. Ruperto N,
   4. Kenwright A,
   5. Wright S,
   6. Calvo I,
   7. et al.

   Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Ilowite NT,
   2. Prather K,
   3. Lokhnygina Y,
   4. Schanberg LE,
   5. Elder M,
   6. Milojevic D,
   7. et al.

   Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014;66:2570–9.

   OpenUrlCrossRef
8. 8.↵
   1. Wallace CA,
   2. Ruperto N,
   3. Giannini E

   . Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290–4.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Wallace CA,
   2. Giannini EH,
   3. Huang B,
   4. Itert L,
   5. Ruperto N

   . American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929–36.

   OpenUrlCrossRef
10. 10.↵
    1. Magni-Manzoni S,
    2. Ruperto N,
    3. Pistorio A,
    4. Sala E,
    5. Solari N,
    6. Palmisani E,
    7. et al.

    Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120–7.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Consolaro A,
    2. Ruperto N,
    3. Bazso A,
    4. Pistorio A,
    5. Magni-Manzoni S,
    6. Filocamo G,
    7. et al.

    Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Consolaro A,
    2. Bracciolini G,
    3. Ruperto N,
    4. Pistorio A,
    5. Magni-Manzoni S,
    6. Malattia C,
    7. et al.

    Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366–74.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Consolaro A,
    2. Ruperto N,
    3. Bracciolini G,
    4. Frisina A,
    5. Gallo MC,
    6. Pistorio A,
    7. et al.

    Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014;73:1380–3.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. De Benedetti F,
    2. Brunner H,
    3. Ruperto N,
    4. Schneider R,
    5. Xavier R,
    6. Allen R,
    7. et al.

    Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol 2015;67:840–8.

    OpenUrl
15. 15.↵
    1. Consolaro A,
    2. Ravelli A

    . Defining criteria for disease activity states in juvenile idiopathic arthritis. Rheumatology 2016;55:595–6.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Woo P,
    2. Southwood TR,
    3. Prieur AM,
    4. Doré CJ,
    5. Grainger J,
    6. David J,
    7. et al.

    Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Vojinovic J,
    2. Damjanov N,
    3. D’Urzo C,
    4. Furlan A,
    5. Susic G,
    6. Pasic S,
    7. et al.

    Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011;63:1452–8.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Limenis E,
    2. Feldman BM,
    3. Achonu C,
    4. Batthish M,
    5. Lang B,
    6. Mclimont M,
    7. et al.

    Proposed core set of items for measuring disease activity in systemic juvenile idiopathic arthritis. J Rheumatol 2018;45:115–21.

    OpenUrlAbstract/FREE Full Text